Evaluation of clearance mechanisms with transscleral drug delivery

Investigative Ophthalmology and Visual Science

Volumn 51, Issue 10, 2010, Pages 5205-5212

  Lee, Sung Jin ^a   He, Weiling ^b   Robinson, Shaun B ^b   Robinson, Michael R ^c   Csaky, Karl G ^b   Kim, Hyuncheol ^b,d  

^a Soonchunhyang University   (South Korea)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c ALLERGAN INC   (United States)

^d Sogang University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORESCEIN SODIUM; IMMUNOGLOBULIN G; CD31 ANTIGEN; CELL SURFACE RECEPTOR; DRUG DERIVATIVE; FLUORESCEIN; FLUORESCENT DYE; HYDROXYPROPYLMETHYLCELLULOSE; LYVE 1 PROTEIN, RAT; LYVE-1 PROTEIN, RAT; METHYLCELLULOSE;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG ELIMINATION; FEMALE; HYDROPHILICITY; IMMUNOHISTOCHEMISTRY; LYMPH VESSEL; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT; SCLERA; TRANSSCLERAL DRUG DELIVERY; ANIMAL; CONJUNCTIVA; DRUG IMPLANT; FLUORESCENT ANTIBODY TECHNIQUE; LONG EVANS RAT; METABOLISM; RETINA; VASCULARIZATION;

ANIMALS; ANTIGENS, CD31; CONJUNCTIVA; DRUG DELIVERY SYSTEMS; DRUG IMPLANTS; FEMALE; FLUORESCEIN; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; FLUORESCENT DYES; LYMPHATIC VESSELS; METHYLCELLULOSE; RATS; RATS, LONG-EVANS; RECEPTORS, CELL SURFACE; RETINA; SCLERA;

EID: 77958120706     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.10-5337     Document Type: Article

References (36)

1. Lee P, Wang CC, Adamis AP. Ocular neovascularization: an epidemiologic review. Surv Ophthalmol. 1998;43:245-269.
2. Aiello LP, Pierce EA, Foley ED, et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci U S A. 1995;92:10457-10461.
3. Adamis AP, Shima DT, Tolentino MJ, et al. Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch Ophthalmol. 1996;114:66-71.
4. Duvvuri S, Majumdar S, Mitra AK. Drug delivery to the retina: challenges and opportunities. Expert Opin Biol Ther. 2003;3: 45-56.
5. Bourlais CL, Acar L, Zia H, Sado PA, Needham T, Leverge R. Ophthalmic drug delivery systems-recent advances. Prog Retin Eye Res. 1998;17:33-58.
6. Lang JC. Ocular drug delivery conventional ocular formulations. Adv Drug Deliv Rev. 1995;16:39-43.
7. Choi YJ, Oh IK, Oh JR, Huh K. Intravitreal versus posterior subtenon injection of triamcinolone acetonide for diabetic macular edema. Korean J Ophthalmol. 2006;20:205-209.
8. Cardillo JA, Melo LA Jr, Costa RA, et al. Comparison of intravitreal versus posterior sub-Tenon's capsule injection of triamcinolone acetonide for diffuse diabetic macular edema. Ophthalmology. 2005;112:1557-1563.
9. Foster CS, de la Maza MS. The Sclera. New York: Springer-Verlag; 1994.
10. Edwards A, Prausnitz MR. Fiber matrix model of sclera and corneal stroma for drug delivery to the eye. Am Inst Chem Eng J. 2004; 44:214-225.
11. Olsen TW, Aaberg SY, Geroski DH, Edelhauser HF. Human sclera: thickness and surface area. Am J Ophthalmol. 1998;125:237-241.
12. Olsen TW, Edelhauser HF, Lim JI, Geroski DH. Human scleral permeability: effects of age, cryotherapy, transscleral diode laser, and surgical thinning. Invest Ophthalmol Vis Sci. 1995;36:1893-1903.
13. Nicoli S, Ferrari G, Quarta M, et al. Porcine sclera as a model of human sclera for in vitro transport experiments: histology, SEM, and comparative permeability. Mol Vis. 2009;15:259-266.
14. Kim H, Robinson MR, Lizak MJ, et al. Controlled drug release from an ocular implant: an evaluation using dynamic three-dimensional magnetic resonance imaging. Invest Ophthalmol Vis Sci. 2004;45: 2722-2731.
15. Gilger BC, Salmon JH, Wilkie DA, et al. A novel bioerodible deep scleral lamellar cyclosporine implant for uveitis. Invest Ophthalmol Vis Sci. 2006;47:2596-2605.
16. Robinson MR, Lee SS, Kim H, et al. A rabbit model for assessing the ocular barriers to the transscleral delivery of triamcinolone acetonide. Exp Eye Res. 2006;82:479-487.
17. Flett MM, Going JJ, Stanton PD, Cooke TG. Sentinel node localization in patients with breast cancer. Br J Surg. 1998;85:991-993.
18. Pavlista D, Eliska O. Cutaneous and subcutaneous lymphatic drainage of the breast. Lymphology. 2005;38:92-102.
19. Pelizzo MR, Merante Boschin I, Toniato A, et al. Sentinel node mapping and biopsy in thyroid cancer: a surgical perspective. Biomed Pharmacother. 2006;60:405-408.
20. Bellnier DA, Greco WR, Parsons JC, Oseroff AR, Kuebler A, Dougherty TJ. An assay for the quantitation of photofrin in tissues and fluids. Photochem Photobiol. 1997;66:237-244.
21. Jin M, Barron E, He S, Ryan SJ, Hinton DR. Regulation of RPE intercellular junction integrity and function by hepatocyte growth factor. Invest Ophthalmol Vis Sci. 2002;43:2782-2790.
22. Zhou J, He S, Zhang N, et al. Neutrophils compromise retinal pigment epithelial barrier integrity. J Biomed Biotechnol. 2010; 289360.
23. Kim SH, Lutz RJ, Wang NS, Robinson MR. Transport barriers in transscleral drug delivery for retinal diseases. Ophthalmic Res. 2007;39:244-254.
24. Bill A. Movement of albumin and dextran through the sclera. Arch Ophthalmol. 1965;74:248-252.
25. Ahmed I, Gokhale RD, Shah MV, Patton TF. Physicochemical determinants of drug diffusion across the conjunctiva, sclera, and cornea. J Pharm Sci. 1987;76:583-586.
26. Edelhauser HF, Maren TH. Permeability of human cornea and sclera to sulfonamide carbonic anhydrase inhibitors. Arch Ophthalmol. 1988;106:1110-1115.
27. Maurice DM, Polgar J. Diffusion across the sclera. Exp Eye Res. 1977;25:577-582.
28. Cruysberg LP, Nuijts RM, Geroski DH, Koole LH, Hendrikse F, Edelhauser HF. In vitro human scleral permeability of fluorescein, dexamethasone-fluorescein, methotrexate-fluorescein and rhodamine 6G and the use of a coated coil as a new drug delivery system. J Ocul Pharmacol Ther. 2002;18:559-569.
29. Ambati J, Canakis CS, Miller JW, et al. Diffusion of high molecular weight compounds through sclera. Invest Ophthalmol Vis Sci. 2000;41:1181-1185.
30. Bill A. Blood circulation and fluid dynamics in the eye. Physiol Rev. 1975;55:383-417.
31. Bellhorn RW. Permeability of blood-ocular barriers of neonatal and adult cats to fluorescein-labeled dextrans of selected molecular sizes. Invest Ophthalmol Vis Sci. 1981;21:282-290.
32. Collin HB. Ocular lymphatics. Am J Optom Arch Am Acad Optom. 1966;43:96-106.
33. Sugar HS, Riazi A, Schaffner R. The bulbar conjunctival lymphatics and their clinical significance. Trans Am Acad Ophthalmol Otolaryngol. 1957;61:212-223.
34. Gray H, Lewis WH. Anatomy of the Human Body. Philadelphia: Lea & Febiger; 1918.
35. Singh D. Conjunctival lymphatic system. J Cataract Refract Surg. 2003;29:632-633.
36. Supersaxo A, Hein WR, Steffen H. Effect of molecular weight on the lymphatic absorption of water-soluble compounds following subcutaneous administration. Pharm Res. 1990;7:167-169.